- Home
- HSCS vs GRI Comparison
HSCS vs GRI Comparison
Compare HSCS & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- GRI
- Stock Information
- Founded
- HSCS 2007
- GRI 2018
- Country
- HSCS United States
- GRI United States
- Employees
- HSCS N/A
- GRI N/A
- Industry
- HSCS Medical Specialities
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- GRI Health Care
- Exchange
- HSCS Nasdaq
- GRI Nasdaq
- Market Cap
- HSCS 3.7M
- GRI 3.4M
- IPO Year
- HSCS 2022
- GRI N/A
- Fundamental
- Price
- HSCS $3.38
- GRI $1.39
- Analyst Decision
- HSCS Strong Buy
- GRI Strong Buy
- Analyst Count
- HSCS 2
- GRI 2
- Target Price
- HSCS $13.00
- GRI $22.00
- AVG Volume (30 Days)
- HSCS 139.1K
- GRI 234.0K
- Earning Date
- HSCS 09-11-2025
- GRI 08-14-2025
- Dividend Yield
- HSCS N/A
- GRI N/A
- EPS Growth
- HSCS N/A
- GRI N/A
- EPS
- HSCS N/A
- GRI N/A
- Revenue
- HSCS $4,350.00
- GRI N/A
- Revenue This Year
- HSCS $21,003.45
- GRI N/A
- Revenue Next Year
- HSCS $533.33
- GRI N/A
- P/E Ratio
- HSCS N/A
- GRI N/A
- Revenue Growth
- HSCS N/A
- GRI N/A
- 52 Week Low
- HSCS $2.36
- GRI $1.10
- 52 Week High
- HSCS $6.47
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- HSCS 44.73
- GRI 45.36
- Support Level
- HSCS $3.33
- GRI $1.15
- Resistance Level
- HSCS $3.82
- GRI $1.28
- Average True Range (ATR)
- HSCS 0.32
- GRI 0.13
- MACD
- HSCS 0.00
- GRI -0.02
- Stochastic Oscillator
- HSCS 52.69
- GRI 23.76
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.